Google (GOOGL.US) AI pharmaceutical company Isomorphic Labs launches new financing: Raised $2.1 billions five months ago, current round aims for a $50 billions valuation
Isomorphic Labs, a DeepMind spin-off, is in talks for new financing, with its valuation potentially reaching up to $50 billions. This comes only five months after its $2.1 billions Series B funding round.
According to Golden Ten Data APP, sources reveal that Isomorphic Labs, an AI drug development startup spun out from Google DeepMind under Alphabet (GOOGL.US), is holding preliminary discussions for a new funding round, targeting a valuation of at least $40 billion.
One of the sources stated that the valuation for this round could be as high as $50 billion. The sources indicated that the fundraising is not yet complete and details may still change. Isomorphic has not responded to requests for comment.
Just five months ago, Isomorphic Labs completed a $2.1 billion Series B funding round. At that time, the company's CEO Demis Hassabis (also serving as DeepMind chairman) said that Alphabet provided "a substantial portion" of the round’s financing but declined to disclose Alphabet's stake or the company’s valuation.
Hassabis previously served as head of DeepMind. In August this year, he announced his transition to chairman, took up the role of chief scientist at Alphabet, and continued as CEO of Isomorphic.
Headquartered in London, Isomorphic Labs was founded in 2021, originating from DeepMind, and aims to advance further on the laboratory’s groundbreaking AlphaFold protein folding model. It is competing with numerous companies seeking to apply the latest AI technologies to the pharmaceutical sector, including OpenAI, which released a life sciences research model this year.
Although AI developers have promised to significantly reduce the time and cost of drug development, few companies have advanced to the clinical trial stage, and none have yet brought a drug to market. Hassabis has stated his goal is to reduce the new drug development cycle from several years to just a few months.
Isomorphic Labs has announced collaborations with major pharmaceutical companies such as Eli Lilly (LLY.US) and Novartis (NVS.US), stating it will focus on the treatment of cancer and immune diseases. In addition to working with pharmaceutical companies and providing its AI drug discovery model, Isomorphic also plans to independently design and develop drugs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OpenAI's annualized revenue aims for $70 billions, with enterprise business as a driving force
According to sources familiar with the matter, OpenAI is expected to reach or exceed an annualized revenue of 7 billion dollars by the end of this year, mainly driven by the growth of its enterprise business.

October 9 Crypto News and Market Trends | BTC/ETH/SOL Resistance & Support
Wells Fargo lowers BlackRock's target price to $1,230.
Australian stock market rises due to broad index gains; Firmus shelving IPO boosts tech stocks
Updated to market close Firmus, backed by Nvidia, cancels $5 billion IPO plan; tech stocks see their biggest weekly gain in a week; Benchmark index posts gains for the second consecutive week Jasmeen Ara Islam Shaikh, Reuters, October 9 – Australian stocks rose on Friday as bargain hunters bought shares after a recent benchmark pullback; at the same time, Firmus’s decision to shelve its $5 billion IPO plan triggered an inflow of funds into local software stocks. The benchmark S&P/ASX 200 .AXJO rose 0.6% on Friday to close at 8,716.6 points after two consecutive days of declines. For the week, the index rose 0.4%, posting gains for a second straight week. Globally, comments from US President Trump that the US would pause strikes against Iran ahead of the November midterm elections provided a slight lift to market sentiment. Domestically in Australia, markets are closely watching September quarter inflation data to be released later this month, as well as awaiting the Reserve Bank of Australia’s last two policy meetings of the year in November and December. On the day, tech stocks .AXIJ jumped as much as 3.1% after data center operator Firmus, backed by Nvidia NVDA.O, called off its IPO due to lukewarm market response. Maas Group MGH.AX, a 3.2% shareholder in Firmus, resumed trading after a morning halt and saw its shares plunge as much as 10.7%. David Tuckwell, Chief Investment Officer at ETF Shares, said Firmus’s withdrawal was positive for local tech stocks as it kept fund managers’ money in existing listed shares and avoided forced rebalancing for index funds. He added that after extended selling, valuations in the sector were oversold and now operating on their own momentum. However, weak demand for Firmus indicated that investors preferred enterprises with solid performance, rather than shunning tech stocks entirely. WiseTech Global WTC.AX, Xero XRO.AX, and Life360 360.AX rose 4.2%, 3.5%, and 4.1% respectively. As gold prices edged up, gold miners .AXGD gained 1.9%, the sector's biggest gain in more than two weeks. GOL/ Weighed down by softer iron ore and copper prices, the overall mining index dipped 0.2%. IRONORE/ MET/L Financial stocks .AXFJ rebounded 0.5% after declines over the previous two sessions. Energy stocks .AXEJ edged higher by 0.2%, marking four straight gains despite weaker early oil prices. O/R Across the Tasman Sea, New Zealand’s S&P/NZX 50 index .NZ50 closed up 0.4% at 13,749.35 points. (For the convenience of non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or omitted context in automated translations, Reuters does not guarantee the accuracy of such texts and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.) For more on "Schedules & Data": US earnings calendar RESF/US, Wall Street outlook for the week .N/O, Global economic outlook DATA/ ... See all the latest market headlines and breaking news at NEWS1.

